In her 29 years at SV, Kate’s biotech investments have resulted in the launch of six drugs for the treatment of patients with inflammatory and autoimmune disease and cancer.
Kate co-leads biotech investments and activities and her investments include small-molecule, biotherapeutic and gene therapy drug discovery and development projects as well as drug discovery platforms in a broad range of clinical areas.
Kate played an active role in setting up the Dementia Discovery Fund (DDF), an SV managed fund, and serves on the DDF Investment Committee.
Prior to joining SV, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm.
Outside of SV, Kate won the Lifetime Achievement Award, presented by the BioIndustry Association UK in January 2017. She also serves on the Board of the Francis Crick Institute. At weekends Kate spends time in Wales where she rides horses and mountain bikes, grows vegetables and competes in bog snorkelling competitions.
In May 2020 Kate was appointed Chair of the UK Vaccine Taskforce reporting to the Prime Minster to lead UK efforts to find and manufacture a COVID-19 vaccine on a six month engagement stepping down as Chair in December 2020. On December 8th 2020 the UK started COVID-19 vaccinations - the first Western country to do so.
First class degree, Biochemistry, University of Oxford; MBA, Harvard Business School (Baker Scholar)